REPL News and Press, Replimune Group Inc. From 02/09/23

Replimune Group press release ( NASDAQ: REPL ): Q3 GAAP EPS of -$0.69 beats by $0.08 . Cash and cash equivalents of $616.38M For further details see: Replimune Group GAAP EPS of -$0.69 beats by $0.08

Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous sq...

WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimun...

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), today announced the grant of inducement equity awards to Chris Sarchi, the...

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune’...

WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, w...

Summary Today, we revisit an intriguing oncology developmental company called Replimune Group, Inc. for the first time in more than a year. This week the company added drug giant Roche as a developmental partner and addressed its funding needs. Replimune Group stock has staged a nic...

Replimune Group ( NASDAQ: REPL ) has priced its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50/share. Additionally it has priced its public offering of pre-funded warrants to purchase 4.2M shares of its common stock at a purchase price...

Replimune ( NASDAQ: REPL ) on Wednesday announced a proposed public offering of up to $125M of shares and pre-funded warrants. All securities in the offering will be offered by REPL, the company said in a statement . Earlier in the day, REPL announced a collaboration with ...

Replimune Group ( NASDAQ: REPL ), a biotech focused on cancer immunotherapies, announced a collaboration with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) on Wednesday to study combination therapies for colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Per the terms of the ...